Highlights from the ACR Convergence 2021 International Congress – Slide Kit
Ultime novità in SSc-ILD e PF-ILD presentate al Congresso Internazionale ACR, 5-9 Novembre 2021
|
SSc-ILD:
Continued treatment with nintedanib in patients with SSc-ILD: two-year data from SENSCIS®-ON (Allanore Y et al)
Severity and impact of gastrointestinal symptoms in patients with SSc-ILD treated with nintedanib: data from SENSCIS®-ON (Khanna D et al)
Effect of nintedanib in patients with SSc-ILD and risk factors for rapid decline in forced vital capacity: further analyses of the SENSCIS® trial (Khanna D et al)
Efficacy and safety of nintedanib in patients with systemic sclerosis‑associated ILD (SSc‑ILD) and differing comorbidity burden: subgroup analyses of the SENSCIS trial (Highland KB)
Effect of nintedanib on KL-6 in patients with SSc-ILD in the SENSCIS® trial (Assassi S et al)
Esophageal involvement and gastroesophageal reflux disease in patients with SSc-ILD: data from a sub-study of the SENSCIS® trial (Kreuter M et al)
PF-ILD:
Safety and tolerability of nintedanib in patients with autoimmune disease‑related interstitial lung diseases: pooled data from the SENSCIS and INBUILD trials (Smith V)
Continued treatment with nintedanib in patients with progressive fibrosing autoimmune disease‑related interstitial lung diseases: data from INBUILD‑ON (Matteson EL)
Effect of nintedanib on categorical changes in FVC in patients with progressive fibrosing ILDs: further analyses of the INBUILD trial (Maher TM)
ARTICOLI CORRELATI
Monitoraggio dei pazienti con ILD fibrosante progressive
Nintedanib and immunomodulatory therapy
Inquadramento radiologico della patologia fibrosante progressive